GlassScriptPhysician profile
Dana D Jones
NPI 1225086432
$2,621.00
in general payments reported to CMS, 2019-2025
24 companies · $503 in 2025
The $503 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $105 · 2021: $73.89 · 2022: $161 · 2023: $698 · 2024: $653 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $494.60 | 2019-2024 | |
| Hologic Sales and Service, LLC | $263.86 | 2021-2025 | Aptima |
| Exeltis, USA INC. | $244.66 | 2022-2025 | Slynd |
| Janssen Biotech, INC. | $226.66 | 2023-2024 | Tecvayli, Darzalex, Rybrevant |
| Coopersurgical, INC. | $203.58 | 2023-2025 | Endosee, Summit Doppler, Paragard T 380a |
| Abbvie INC. | $195.90 | 2019-2025 | |
| Myriad Women'S Health, INC. | $157.33 | 2023 | Myrisk |
| Astellas Pharma US INC | $147.02 | 2023-2025 | Veozah |
| Immunogen, INC. | $126.00 | 2023 | Elahere |
| Sage Therapeutics, LLC | $116.96 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $89.57 | 2022-2023 | |
| Organon LLC | $64.08 | 2021-2025 | Jada System |
| Smith+Nephew, INC. | $47.46 | 2019-2025 | Pico 14 |
| Supernus Pharmaceuticals, INC. | $42.20 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $35.96 | 2022-2023 | Gardasil 9 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $30.62 | 2023-2025 | Femring, Intrarosa |
| Ascend Therapeutics US, LLC | $24.46 | 2019 | |
| Medtronic, INC. | $23.55 | 2022 | |
| Agile Therapeutics, INC. | $20.03 | 2022 | |
| Novo Nordisk INC | $17.22 | 2023 | Saxenda, Wegovy |
| Boston Scientific Corporation | $13.15 | 2019 | |
| Duchesnay USA Incorporated | $13.13 | 2019 | |
| Covidien LP | $11.90 | 2019 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.